Anesthesia, General Clinical Trial
Official title:
A Prospective, Randomized, Double-Blinded Study of the Effect on Improved Recovery Using the SEDLine TM for the Titration of Sevoflurane in Elderly Patients Undergoing Non-Cardiac Surgery After Beta-Adrenergic Blockade
Verified date | February 2015 |
Source | Stanford University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
Asses the effect of the use of Patient State Index (PSI) monitoring on difference in
emergence profiles in the elderly (age >65 yrs) population to develop a cost-benefit
profile.
Assess differences in Quality of Life using the QoR-40 (a validated 40-item questionnaire on
quality of recovery from anesthesia) between the two treatment groups.
Status | Completed |
Enrollment | 67 |
Est. completion date | June 2012 |
Est. primary completion date | June 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 65 Years and older |
Eligibility |
Inclusion Criteria: - Patient is male or female. - Patient is 65 years of age or older. - Patient has a physical status between ASA I and III. (Appendix C). - Patient scheduled for general anesthesia for non-cardiac surgery expected to last at least one hour. - Patient able to communicate in English. - Patient has signed an approved informed consent. Exclusion Criteria: - Patient's age is less than 65 years - Anesthetic duration of less than one hour expected - Treatment of beta blockers contra-indicated - Not a candidate for general anesthesia - Patient requires regional anesthesia with general anesthesia. - ASA physical status of IV or V. (Appendix C) - Patient has known drug or alcohol abuse. - Patient has scalp or skull abnormalities such as psoriasis, eczema, angioma, scar tissue, burr holes, cranial implants (such as plates, shunts, etc.). - Patient has experienced a head injury with loss of consciousness within the last year. - Patient has known neurological and psychiatric disorder that interferes with the patient's level of consciousness. - Known concurrent chronic usage of psychoactive or anticonvulsive drugs within the last 90 days, or any use in the last 7 days (i.e. tricyclic antidepressants, MAO inhibitors, lithium, SSRIs, neuroleptics, anxiolytics or antipsychotics). - Patient has any medical condition which, in the judgment of the investigator, renders them inappropriate for participation in this study, such as Guillen Bare syndrome - Known hypersensitivity to the intended anesthetic agents including significant post-operative nausea or vomiting. - Uncontrolled hypertension (unresponsive to medication): Systolic BP > 180 mmHg or Diastolic BP > 105 mmHg - Pre-Op baseline heart rate < 45 beats per minute - Weight 50% greater than ideal body weight - Already monitored for EP or EEG, i.e., Spinal cord cases - Actual anesthetic duration < 1 hour (assessed after emergence). |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
United States | Stanford University School of Medicine | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
Stanford University | Hospira, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to Extubation | The exact time from end of last anesthetic drug to time of tracheal extubation. | Measured from time of end anesthesia to time of tracheal extubation. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06063798 -
Respiratory Effects of Flow-Controlled Ventilation and Jet Ventilation in Patients Undergoing Laryngotracheal Surgery
|
N/A | |
Not yet recruiting |
NCT05035069 -
Efficacy and Safety of Ciprofol Compared to Propofol for Nonintubated General Anesthesia in Patients Undergoing TAVR
|
Phase 4 | |
Completed |
NCT03861364 -
Hemodynamics During Induction of General Anesthesia With High and Low Propofol Dose.
|
Phase 4 | |
Completed |
NCT02711280 -
The Effect of Anesthetics on Oxidative Stress and Apoptosis Status in Children
|
N/A | |
Completed |
NCT01199471 -
Estimate the Behavior of Chinese Anesthesiologists Practicing General Anesthesia With Sevoflurane
|
N/A | |
Completed |
NCT00917033 -
Tracheal Intubation of Morbidly Obese Patients. GlideScope Versus Direct Laryngoscopy
|
Phase 4 | |
Completed |
NCT00391885 -
Target-controlled Infusion of Propofol and Remifentanil During General Anaesthesia Guided by Entropy
|
Phase 4 | |
Completed |
NCT00552617 -
A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971)
|
Phase 2 | |
Completed |
NCT03705026 -
Relationship Between Genetic Polymorphism and Postoperative Nausea and Vomiting in Chinese Han Population
|
||
Completed |
NCT00552929 -
A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974)
|
Phase 2 | |
Completed |
NCT00475215 -
Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017)
|
Phase 3 | |
Completed |
NCT00298831 -
Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)
|
Phase 3 | |
Recruiting |
NCT03943745 -
EEG Changes During Induction of Propofol Anesthesia
|
||
Completed |
NCT03697642 -
Nasopharyngeal Airway Guide Nasogastric Tube Placement
|
N/A | |
Completed |
NCT04595591 -
Observation of Propofol Titration at Different Speeds
|
N/A | |
Not yet recruiting |
NCT05841316 -
The ED95 Dose of Sugammadex to Reverse Rocuronium-Induced Deep Neuromuscular Block Back to Shallow Neuromuscular Block
|
||
Completed |
NCT04532502 -
Impact of Anesthetic Environment the Sex Ratio of the Children of Female Assistants
|
||
Completed |
NCT03330236 -
EEG - Guided Anesthetic Care and Postoperative Delirium
|
N/A | |
Recruiting |
NCT06205212 -
High-flow Nasal Oxygenation During Preoxygenation and Atelectasis
|
N/A | |
Completed |
NCT00379613 -
Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942)
|
Phase 2 |